mRNA Vaccine from Pfizer Inc. and BioNtech SE Has Successful Test
The experimental coronavirus vaccine from Pfizer Inc. and BioNtech SE has shown now in early testing and clinicals that it is safe and had even promoted the production of antibodies against COVID-19.
The vaccine, an mRNA Vaccine, was featured in a trial consisting of 45 healthy adults split up into different groups. 24 people received two injections with two different doses of the mRNA vaccine, 12 different people got single shot with a very high dose, and nine patients in the test received two placebo injections. The group of patients that received two injections produced the highest level of antibodies.
Peter Hotez, a vaccine researcher and dean of the National School of Tropical Medicine at Baylor College of Medicine said, “I see this as the first good news we’ve seen from Operation Warp Speed,” Operation Warpspeed being the US government’s program to develop a vaccine as quickly as possible. the vaccine produced “significant levels of virus neutralizing antibody,” Hotez said.
BNT162b1 is the name of the vaccine candidate and it is currently undergoing scientific peer review. The companies are looking to produce 100 million doses by the end of 2020 if the vaccine proves to be successful.
This is a developing story and we will be following it in the coming weeks. Be sure to check back regularly at the ABN blog for updates.